03/27/2024 5:34 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024 8:36 AM | BlackRock Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/05/2024 5:24 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2024 5:16 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024 5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024 5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
01/25/2024 5:13 AM | Phathom Pharmaceuticals, Inc. (Issuer) Takeda Pharmaceutical (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/25/2024 5:11 AM | Phathom Pharmaceuticals, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
01/19/2024 5:03 AM | Equillium, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13G | |
01/16/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/14/2023 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/30/2023 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/13/2023 5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023 5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/26/2023 5:22 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023 5:21 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/18/2023 5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/02/2023 5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/28/2023 5:17 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/11/2023 5:50 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/01/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023 5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/12/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2023 5:26 AM | Sequeira Ramona (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:33 AM | Bitetti Teresa Marie (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:35 AM | Takeda Pharmaceutical (Subject) Wozniewski Thomas Otto Claus (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:16 AM | Kim Julie So-Young (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:20 AM | Duprey Lauren Rusckowski (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:22 AM | Pignagnoli Agosti Marcello (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:24 AM | Lugogo Mwana Pietrina (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:06 AM | Ricci Gabriele (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:09 AM | Plump Andrew Stewart (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:12 AM | Greco Gerard M (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2023 5:14 AM | Platford Giles Richard (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/06/2023 5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/03/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023 5:35 AM | Takeda Pharmaceutical (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
06/28/2023 5:00 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Top Project Outperforms BTC in 2023… (Ad) According to a recently published report…
One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen.
And now, this crypto coin is set to soar in the parabolic bull run projected in 2024. Just click here for instant access to the #1 Coin for 2024. |
06/28/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
06/23/2023 5:13 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/23/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/09/2023 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/01/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:11 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/30/2023 5:14 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2023 6:08 AM | Calithera Biosciences, Inc. (Issuer) Takeda Pharmaceutical (Reporting) Takeda Ventures, Inc. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/26/2023 6:08 AM | Calithera Biosciences, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
05/17/2023 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2023 5:09 AM | Takeda Pharmaceutical (Filer)
| Form SD Specialized Disclosure Report | |
05/11/2023 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2023 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/30/2023 5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |